RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CNS Pharmaceuticals Stock

CNS Pharmaceuticals Market capitalization 2024

CNS Pharmaceuticals Market capitalization

10,616.82 USD

Ticker

CNSP

ISIN

US18978H1023

WKN

A2PNH4

In 2024, CNS Pharmaceuticals's market cap stood at 10,616.82 USD, a -99.76% increase from the 4.39 M USD market cap in the previous year.

The CNS Pharmaceuticals Market capitalization history

YEARMarket Capitalization (undefined USD)
20230.01
20220.6
20212.42
20203.09
20192.73
2018-
2017-

CNS Pharmaceuticals Aktienanalyse

What does CNS Pharmaceuticals do?

CNS Pharmaceuticals Inc is an American pharmaceutical company specializing in the development and marketing of innovative therapies for patients with severe and life-threatening central nervous system disorders. The company was founded in 2017 and is headquartered in Houston, Texas. CNS Pharmaceuticals Inc's history began with the realization that there is an urgent need for new and more effective treatment methods for central nervous system tumors. The company's founders therefore identified promising new drugs based on the latest research findings and began testing them in clinical trials. CNS Pharmaceuticals Inc's business model focuses on innovative research and development of new drugs, as well as close collaboration with leading scientists and medical professional societies. The company aims to bring its medications to market quickly and cost-effectively, without compromising on quality or safety. The various divisions of CNS Pharmaceuticals Inc include research, development, production, and marketing of its drugs. The company has launched a variety of research projects aimed at developing new therapies for patients with brain tumors and other severe central nervous system disorders. One of CNS Pharmaceuticals Inc's most well-known products is Berubicin, a promising drug for the treatment of glioblastoma, a particularly aggressive type of brain tumor. Berubicin is a novel DNA-intercalating drug that is highly effective and has low toxicity. Clinical trials have already shown that Berubicin can extend the survival time of patients. Another important product of CNS Pharmaceuticals Inc is WP1244, a drug against glioblastoma based on an innovative technology that improves the uptake of drugs into cells. Preclinical studies have already shown that WP1244 is able to stop tumor growth and destroy cancer cells. CNS Pharmaceuticals Inc has a strong network of partner companies and distribution partners that help with the marketing and dissemination of its products. The company works closely with leading cancer centers and research institutions to further improve the effectiveness of its drugs and provide patients with a higher level of safety and quality of life. Overall, CNS Pharmaceuticals Inc has established itself as a dynamic and innovative company with a high level of expertise in the development of new drugs. The company aims to expand its position as a leading provider of therapies for patients with brain tumors and other severe central nervous system disorders, and to sustainably improve the quality of life of affected patients. CNS Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring CNS Pharmaceuticals's Market Capitalization

CNS Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of CNS Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

CNS Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in CNS Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about CNS Pharmaceuticals stock

What is the current CNS Pharmaceuticals market capitalization?

The current market capitalization of CNS Pharmaceuticals is 10,616.82 USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like CNS Pharmaceuticals.

How has the market capitalization of CNS Pharmaceuticals developed in recent years?

The market capitalization of CNS Pharmaceuticals has increased/decreased by -99.76% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of CNS Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of CNS Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of CNS Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does CNS Pharmaceuticals pay?

Over the past 12 months, CNS Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CNS Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of CNS Pharmaceuticals?

The current dividend yield of CNS Pharmaceuticals is .

When does CNS Pharmaceuticals pay dividends?

CNS Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CNS Pharmaceuticals?

CNS Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of CNS Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CNS Pharmaceuticals located?

CNS Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von CNS Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CNS Pharmaceuticals from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did CNS Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of CNS Pharmaceuticals in the year 2023?

In the year 2023, CNS Pharmaceuticals distributed 0 USD as dividends.

In which currency does CNS Pharmaceuticals pay out the dividend?

The dividends of CNS Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CNS Pharmaceuticals

Our stock analysis for CNS Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CNS Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.